ClinicalTrials.gg
CompletedNCT00002336Updated Jan 16, 2015

The Safety and Effectiveness of Clarithromycin in the Prevention of Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients

An interventional study of Clarithromycin in Mycobacterium Avium-intracellular Infection and HIV Infections, sponsored by Abbott. Completed at 22 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2015-01-16.

Sponsored by Abbott · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing clarithromycin in HIV Infections — none open to participants now, none under way, none of them phase 3. Clarithromycin · HIV Infections.

Started
1992
the only one that year
No phase
3 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
3 of 10
Abbott

Among the 10 studies testing clarithromycin in HIV Infections, this one is the only one that started in 1992, is one of 3 with no phase, and was the 1st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 10 studies testing clarithromycin in HIV Infections is open now. The open studies under HIV Infections, anywhere →

Where they have run

About clarithromycin

Clarithromycin: first FDA approval 1991 (BIAXIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing clarithromycin in HIV Infections as a file.
02

Study summary

To determine whether clarithromycin is safe and effective in preventing disseminated Mycobacterium avium Complex in HIV-infected patients with CD4 counts \<= 100 cells/mm3.

03

Conditions studied

  • Mycobacterium Avium-intracellular Infection
  • HIV Infections

Keywords

  • Mycobacterium avium-intracellular Infection
  • Acquired Immunodeficiency Syndrome
  • Clarithromycin
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must have:

  • infection.
  • \<= 100 cells/mm3.
  • No evidence of MAC.
  • of at least 6 months.

Exclusion criteria

Exclusion Criteria

Concurrent Medication:

Excluded:

  • Certain restricted drugs (details not available).

Patients with the following prior conditions are excluded:

History of allergy or to macrolides. Active substance abuse or other conditions that would affect study compliance.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Masking
Double

Interventions

06

Study locations

22 sites
  • Univ of Arizona / Health Science Ctr
    Tucson, Arizona 85724, United States
  • California Med Research Group
    Fresno, California 93726, United States
  • HIV Research Group
    San Diego, California 92102, United States
  • Saint Francis Mem Hosp
    San Francisco, California 94109, United States
  • Kaiser Permanente Med Ctr
    San Francisco, California 94115, United States
  • Santa Clara Valley Med Ctr
    San Jose, California 951282699, United States
  • TheraFirst Med Ctrs Inc
    Fort Lauderdale, Florida 33308, United States
  • Dr Nelson Zide
    Hollywood, Florida 33021, United States
  • Infectious Disease Research Institute Inc
    Tampa, Florida 33614, United States
  • Indiana Univ Hosp
    Indianapolis, Indiana 46202, United States
  • Saint Vincent's Hosp and Med Ctr
    New York, New York 10011, United States
  • SUNY / Health Sciences Ctr at Syracuse
    Syracuse, New York 13210, United States
  • New York Med College / Westchester County Med Ctr
    Valhalla, New York 10595, United States
  • Nalle Clinic
    Charlotte, North Carolina 28207, United States
  • Westover Heights Clinic
    Portland, Oregon 97210, United States
  • Univ of Tennessee
    Memphis, Tennessee 38163, United States
  • Vanderbilt Univ
    Nashville, Tennessee 37212, United States
  • Univ of Texas Southwestern Med Ctr of Dallas
    Dallas, Texas 75235, United States
  • Houston Veterans Administration Med Ctr
    Houston, Texas 77030, United States
  • Audie L Murphy Veterans Administration Hosp
    San Antonio, Texas 78284, United States
  • Salem Veterans Administration Med Ctr
    Salem, Virginia 24153, United States
  • Dr Alan D Tice / Infections Ltd
    Tacoma, Washington 98405, United States
07

References and documents

Publications

  • Pierce M, Crampton S, Henry D, Heifets L, LaMarca A, Montecalvo M, Wormser GP, Jablonowski H, Jemsek J, Cynamon M, Yangco BG, Notario G, Craft JC. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med. 1996 Aug 8;335(6):384-91. doi: 10.1056/NEJM199608083350603. PubMed 8663871 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 1992, a primary completion of Nov 1994 and a completion of Nov 1994. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 1999
First posted
Aug 31, 2001
Start
Nov 1992
Primary completionActual
Nov 1994
CompletionActual
Nov 1994
Last update
Jan 16, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00002336
Lead sponsor
Abbott
First posted
Aug 31, 2001
Start date
Nov 1992
Primary completion
Nov 1994
Completion
Nov 1994
Last update
Jan 16, 2015
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clarithromycin

Start the discussion